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Abstract
Background: The effective therapies for oral cancer patients of stage III and IV are generally surgical excision and
radiation combined with adjuvant chemotherapy using 5-Fu and Cisplatin. However, the five-year survival rate is
still less than 30% in Taiwan. Therefore, evaluation of effective drugs for oral cancer treatment is an important
issue. Many studies indicated that aurora kinases (A, B and C) were potential targets for cancer therapies. Reversine
was proved to be a novel aurora kinases inhibitor with lower toxicity recently. In this study, the potentiality for
reversine as an anticancer agent in oral squamous cell carcinoma (OSCC) was evaluated.
Methods: Effects of reversine on cell growth, cell cycle progress, apoptosis, and autophagy were evaluated mainly
by cell counting, flow cytometry, immunoblot, and immunofluorescence.
Results: The results demonstrated that reversine significantly suppressed the proliferation of two OSCC cell lines
(OC2 and OCSL) and markedly rendered cell cycle arrest at G2/M stage. Reversine also induced cell death via both
caspase-dependent and -independent apoptosis. In addition, reversine could inhibit Akt/mTORC1 signaling
pathway, accounting for its ability to induce autophagy.
Conclusions: Taken together, reversine suppresses growth of OSCC via multiple mechanisms, which may be a
unique advantage for developing novel therapeutic regimens for treatment of oral cancer in the future.
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Background
Oral cancer is listed as the sixth common tumor world-
wide [1]. In Taiwan, oral cancer is even the fourth lead-
ing cause of cancer death for males [2]. Oral squamous
cell carcinoma (OSCC) is the most common neoplasia
and is found frequently in oral cavity such as cheek,
gum, and tongue [3]. Although cigarette and alcohol are
considered as two major risk factors of oral carcinogen-
esis [4], occurrence of oral cancer was proved to be
tightly associated with betel quid chewing in Taiwan
and in south-east Asia [4,5]. So far, surgery and radia-
tion treatments in combination with chemicals like 5-Fu
or Cisplatin are the major therapeutic strategies for oral
cancers [6,7]. However, surgery and radiation treatments
inevitably cause negative impacts on patients’ appear-
ance and oral functions like chewing and speaking. In
spite of 5-Fu or Cisplatin adjuvant treatments, 5 years
survival rate of oral cancer patients is only 30% [6]. A
more efficient and safer anticancer drug may be helpful
to minimize the surgery area or to delay disease
progress.
Aurora kinase, which includes A, B and C members in
mammals, is belonged to serine/threonine kinase. Aur-
ora kinase A and B were demonstrated to function at
mitosis. Like some cell cycle regulators, expression of
aurora kinase A and B oscillates during cell division
[8,9]. Aurora kinase A controls the entrance into mitosis
by regulating cyclin B/CDK1 [10]. Aurora kinase B
phosphorylates Ser10 on Histone H3 to regulate
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survivin, and borealin to form chromosomal passenger
complex for chromosome arrangement during cytokin-
esis [11-14]. Aurora kinase C is mainly expressed in tes-
tis and is involved in spermatogenesis [15,16]. Several
studies had implicated the relationship between aurora
kinases and carcinogenesis [17]. Overexpression of aur-
ora kinase A produces several centrosomes in fibroblast,
resulting in aneuploidy [11]. Both aurora kinase A (also
named as STK15) and B had been suggested to be cor-
related with oral cancer [18,19]. Despite its major
expression site in testis, aurora kinase C appears occa-
sionally in some cancer tissues [20].
Currently, aurora kinases inhibitors VX680 and PHA-
730358 are clinically tested [21,22]. In Myc-overexpressed
cells, treatment of VX680 was reported to induce apoptosis
or the subsequent autophagy-mediated death in residual
cells [23]. Autophagy is a mechanism by which cells
enhance metabolism of damaged organelles or recycle dis-
pensable materials to survive harsh conditions like starva-
tion. In the initiation of autophagy, LC3 (type I) could be
lipidated and became active form (type II), which would
interact with cellular lipid to facilitate aggregation of autop-
hagosome [24]. Therefore, VX680 treatment induces both
apoptosis and autophagy, leading to increase the chance of
oncolysis. Based on the fact that VX680 successfully inter-
feres with growth of various malignant cell lines obtained
from different tissues [25], aurora kinases become valuable
targets for cancer therapies. Therefore, it is important to
identify effective inhibitors for aurora kinases and under-
stand the mechanisms for the inhibitory effects.
Reversine (2-(4-morpholinoanilino)-6-cyclohexylami-
nopurine) was found originally to promote cell dediffer-
entiation [26,27]. Recently, aurora kinases were proved
to be the targets of reversine [28]. Compared with
VX680, reversine is less toxic to cells from healthy
donors but is efficient to reduce cell colony formation
from acute myeloid leukemia (AML) patients. Besides,
reversine was also proved to block proliferation or to
induce programmed cell death in different malignant
c e l ll i n e ss u c ha sH C T - 1 1 6[ 2 9 ] .In vivo,r e v e r s i n e
restricts tumor growth from xenograft models experi-
ment [29,30]. These data increase the possibility that
reversine may be a potential candidate for treating oral
cancers. In this study, we investigate the mechanisms
behind the suppressive effects of reversine on OSCC
cells and conclude that reversine is a broad-spectrum
agent involved in cell cycle arrest, apoptosis, caspase-
independent cell death and autophagy.
Materials and methods
Cell culture and Transfection
Two OSCC cell lines (OCSL and OC2), which were
derived from two males with habits of drinking,
smoking, and betel quid chewing in Taiwan, were main-
tained in RPMI1640 medium supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin.
C e l l sw e r ec u l t u r e da t3 7 ° Cs u p p l i e dw i t h5 %C O 2.
About 1.5 × 10
5 cells were seeded in 6-wells plates.
Then, cells were transfected with Lipofectamine 2000
(Invitrogen) according to manufacturer’s instruction.
Reagents and antibodies
Reversine was purchased from Cayman. Dimethyl sulf-
oxide (DMSO) and 3-methyladenine (3-MA) were from
Sigma. Trypan blue was from BioWest. Z-VAD-fmk and
wortmannin was from Merck. Antibodies against cas-
pase 3, 8, 9, phospho-aurora A/B/C, Cdc2, mTOR,
phospho-mTOR, phospho-p70S6K, and rapamycin were
from Cell Signaling. Antibodies against AIF, Bcl-xL and
Bid were from Epitomics. Antibodies of total and phos-
phor-Akt were from Santa Cruz. Antibody against LC3
was from Abgent. Other antibodies were all from
GeneTex.
Cells viability analysis
1×1 0
5 cells were seeded into 6-wells plates. After che-
micals treatment for indicated times, cells were collected
by trpsinization, centrifuged, resuspended in 500 μlP B S
and stained with 0.5% trypan blue. The unstained cells
were quantified using a counting chamber.
Cell cycle analysis
1×1 0
5 cells were seeded in 6-wells plates and serum
starved after attachment. After starvation, cells were
treated with chemicals, harvested, washed once with 3
ml PBS, centrifuged, resuspended in 1 ml PBS, and
finally fixed using 1 ml 100% methanol. The fixed cells
were air tightly stored in a 4°C. Before analysis, cells
were washed once with 3 ml PBS, resuspended in 400 μl
PBS, transferred into a 15 ml tube containing 78 μl1 ×
PBS, 2.5 μl RNase (10 mg/ml) and 20 μlp r o p i d i u m
iodide (PI, 1 mg/ml). After incubation in dark for 30
minutes, treated cells were analyzed by BD CANTO II
flow cytometer.
Cell lysates preparation and Western blot
Cells were lysed with M-PER (mammalian protein
extraction reagent, Thermo) containing 0.1% protease
inhibitor cocktail. Mixture was vortexed and incubated
on ice for 5 minutes. After centrifugation at 14,000 g for
15 minutes at 4°C, protein concentration in the superna-
tant part was quantified using BCA protein assay kit
(Thermo). Proper amount of proteins was mixed with
5× Laemmli sample buffer and boiled for 10 minutes.
Samples were run on SDS-PAGE gels and transferred to
PVDF membranes. Specific targets were detected using
proper antibodies, followed by the secondary antibody
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incubation with Immobilon Western Chemiluminescent
HRP substrate (Millipore), the results were detected
using BioSpectrum Imaging System (UVP).
Dual staing of annexin V and propidium iodide (PI)
1×1 0
6 cells were seeded into 10 cm plates, treated with
indicated chemicals, collected by centrifugation. The
pellet cells were stained using Annexin V-FITC detec-
tion kit (Strong Biotech) and analyzed by flow
cytometer.
DNA fragmentation analysis
The preparation of fragmented DNA was according the
method described [31].
Immunofluorescence
Cultured cells were washed twice with PBS and fixed in
ice-cold 4% formaldehyde/PBS for 20 minutes. After
washing three times with PBS again, cells were stained
with anti-AIF antibodies at 4°C with gentle swirling
overnight. Then, cells were incubated with second anti-
bodies conjugated with Alexa 488 at room temperature.
After washing, localization of AIF was observed using a
fluorescence microscope.
Confocal microscope
1.5 × 10
5 cells were seeded in 6-wells plates preloaded
with sterilized glass cover slips. After transfection and/
or chemicals treatment, cells on cover slips were washed
twice with PBS and fixed with 4% paraformaldehyde for
30 minutes at room temperature. After washing three
times with PBS, cover glasses were carefully mounted
onto microscope glasses containing a drop of ProLong
Gold antifade reagent with DAPI (Invitrogen). Finally,
the slides were sealed and analyzed using Olympus con-
focal microscope.
Results
Reversine suppresses the growth of OSCC cells
To evaluate the potential effect of reversine on suppres-
sing OSCC cell growth, two cell lines OCSL and OC2
cells established from the local patients were examined
[32]. The endogenous levels of phosphorylated aurora
kinases were detectable, implying the potential applica-
tion of reversine for suppressing the growth of oral can-
cer cells (Additional file 1A). To prove that aurora
kinase were inhibited in these two cell lines, Serine 10
phosphorylation of histone H3, which was proved to be
a direct downstream target of aurora kinases, were eval-
uated [29,33]. Indeed, reversine obviously inhibited the
Serine 10 phosphorylation of histone H3. This result
suggested that reversine strongly inhibited aurora
kinases in these two OSCC cells (Additional file 1B).
Therefore, the effects of reversine on proliferation of
OC2 and OCSL were checked. As shown in Figure 1, 1
μM reversine was enough to suppress the growth of
both cells. Higher doses of reversine further reduced cell
numbers as early as 12 hours after treatment, indicating
that reversine possessed the effective inhibition ability
against the growth of OSCC cells.
Reversine interferes with the progress of cell cycle
Aurora kinases had been proved to play important roles
in regulating cell division [34]. Inhibition of aurora
kinases resulted in cell cycle arrest or even cell death
[35,36]. To examine whether the cell cycle was affected,
OC2 and OCSL cells were analyzed by flow cytometry
after treating with various doses of reversine at different
time points. The results were shown in Figure 2B. Basi-
cally, the percentage of G2/M cells increased with the
high doses (10 μM) of reversine (Figure 2A upper
panel). Taken In addition, the ratio of cells with 4N
chromatin increased significantly in a dose- and time-
dependent pattern (Figure 2B). Moreover, some cells
with 8N chromatin were also noticed in OCSL cells,
highly suggesting that reversine delayed progress of cell
cycle and affected the processes of cytokinesis. To
further support this notion, we checked the effect of
reversine on the expression of cyclin B1. Reversine
appeared to prolong the expression of cyclin B1 in syn-
chronized OCSL and OC2 cells (Figure 2C). It is known
that the expression of cyclin D1 is required for next cell
cycle entry from M phase. Indeed, in the absence of
reversine treatment (DMSO mock treatment), the levels
of cyclin D1 proteins were up-regulated after 9 hours.
In contrast, reversine treatment had suppressed the pro-
tein level of cyclin D1 throughout the treating period
(Figure 2C). In addition, the levels of Cdc2, a CDK of
G2/M, were not significantly influenced by reversine
(Figure 2C). Taken together, these results indicated that
reversine caused retardation at G2/M phase in the cell
cycle. Moreover, reversine also highly increased subG1
population after 48 hours treatment (Figure 2A lower
panel and 2B), suggesting a possibility that reversine
induced cytotoxic effects at the later stage.
Reversine induces cell death through canonical and non-
canonical apoptosis pathways
The increased subG1 population suggested growth sup-
pression through programmed cell death. Therefore,
OSCC cells were dually stained with annexin V-FITC
and with propidium iodide (PI) to monitor type I pro-
grammed cell death (apoptosis) in the absence or pre-
sence of reversine. Treatment of reversine increased the
population of annexin V positive and PI-positive cells in
a time- and doses-dependent manner as shown in
Figure 3A. Especially, the apoptosis percentage was over
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highly suggesting that reversine was more effective in
OCSL cells, the cell line previously proven more malig-
nant than OC2 [32].
Treatment of reversine obviously resulted in accumu-
lation of cleaved caspase 3 (Figure 3C). This result
further confirmed that reversine could suppress cell
growth through type I programmed cell death. Both
extrinsic and intrinsic pathways are involved in type I
programmed cell death. We showed that the cleaved
caspase 8 was increased after reversine treatment, indi-
cating the activation of extrinsic pathway [37]. On the
other hand, accumulation of processed caspase 9 and
decrease of Bcl family members (Bcl-xL and Bid)
demonstrated that reversine also enhanced intrinsic
pathway. Taken together, these results confirmed that
reversine could suppress the oral cell growth through
the canonical caspase-dependent pathway.
Z-VAD-fmk, a pan-caspase inhibitor, has been used to
check whether drug-induced cell death is through the
caspases pathway. Surprisingly, the number of viable cells
only slightly increased even after treatment of inhibitor
for two days (Figure 4A). It was unlikely due to insuffi-
cient concentration of Z-VAD-fmk inhibitor because of
t h ec o m p l e t ei n h i b i t i o no fc a s p a s e3( F i g u r e4 B ) .I n
addition, DNA ladder under the treatment of both
Z-VAD-fmk and reversine was still observed (Figure 4C).
Taken together, these results suggested that reversine-
induced cell death was mediated mainly through another
caspase-independent programmed cell death. To support
these results, we examined the location of AIF in the
absence or presence of reversine in OC2 cells. AIF was
identified as a marker protein for caspase-independent
apoptosis [38,39]. In normal physiological condition, AIF
is retained in the mitochondrial membrane, where it exe-
cutes the oxidoreductase function [40]. Once activated by
apoptosis, AIF was translocated into the nucleus from
the mitochondrial membrane and causes chromatin con-
densation and DNA fragmentation [41]. As shown in
Figure 4D, AIF was located in the cytoplasm in the
absence of reversine. However, after treatment of 5 μM
reversine for 24 hour, AIF was translocated into the
nucleus in OC2 cells, indicating that reversine can trigger
the non-canonical caspase-independent cell death.
Reversine also induces autophagy
After treatment of reversine, cells showed intracellular
vacuoles as shown in Figure 5A, implying that reversine
may induce the autophagic responses. We checked
whether reversine had an effect on the level of type I
(A)  (B) 
Figure 1 Reversine suppresses OSCC cell growth. OSCC cells OC2 (A) and OCSL (B) were treated with DMSO or various concentrations of
reversine (1 to 50 μM). Cells were harvested, stained by trypan blue and calculated at the 12, 24 and 48 h. Data were expressed as means ± SD
of three independent experiments, each of which was done in triplicate.
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Figure 2 Cell cycle arrests by reversine. (A) OSCC cells were treated with DMSO or different concentrations of reversine (1, 5, 10 μM) for 12,
24 and 48 h. Cells were harvested, stained with PI and applied for flow cytometry analysis. The data were analyzed from three independent
experiments. (B) As in (A), cells were treated with either different doses of reversine at 24 h or 5 μM reversine at indicated time points. The
percentage of cells in each phase of the cell cycle was demonstrated. (C) OSCC cells treated with DMSO or 5 μM reversine were harvested and
analyzed for cell cycle-dependent proteins. The GAPDH protein was used as the loading control.
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Figure 3 Induction of apoptosis by reversine. (A) OSCC cells were treated with DMSO or different concentrations of reversine (5 and 10 μM).
At indicated time points (12, 24 and 48 h), cells were dually stained with annexin V-FITC and PI as described and analyzed by flow cytometry.
The percentage of cells in early apoptosis and early apoptosis plus late apoptosis of OC2 and OCSL cells were evaluated, respectively. All results
were obtained from three independent experiments. * indicated significant difference from the untreated cells (DMSO) (p < 0.05). (B) The
representative figure of flow cytometry from OCSL cells treated as described in (A). (C) OSCC cells harvested from (A) were used to analyze the
expression of apoptosis-related proteins. Cells treated with 50 μM etoposide to induce apoptosis were used as a positive control.
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Figure 4 Induction of caspase-independent cell death by reversine. (A) Two hours before reversine addition, OSCC cells were pre-treated
with or without 20 μM Z-VAD-fmk, followed by treated with or without 5 μM reversine, and harvested at 12, 24 and 48 h later. Cell numbers
were counted as mentioned. (B) OSCC cells in (A) panel at 24th hour were used to monitor the cleaved caspase 3 protein as a marker of
caspase-dependent apoptosis. (C) Similar to (B) panel, OC2 cells were used for DNA fragmentation analysis. (D) OC2 cells were treated with 5 μM
reversine, stained with anti-AIF antibody and DAPI and visualized with a fluorescence microscope (magnification, ×200). AIF was retained in the
cytoplasm in the absence of reversine and translocated into the nucleus after reversine treatment.
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Figure 5 Induction of autophagy by reversine. (A) OC2 cells were treated without (DMSO) or with reversine (5 and 10 μM) for 24 h. Phase-
contrast microscopy were taken with 200× magnification. Autophagic vesicles were observed in cells treated with reversine. (B) OSCC cells were
pre-treated with 1 or 3 mM 3-MA for 2 hours, followed by treatment without or with 10 μM reversine. At indicated time points, cells were
harvested for analyzing the cytoplasmic form LC3-I or the membrane form LC3-II. (C) OCSL cells were transfected with vectors expressing either
GFP or GFP-LC3-II, followed by treatment of 3-MA and/or reversine as described. OSCL cells were analyzed under confocal microscope. (D) The
same as (C) except that two different concentrations of 3-MA were evaluated. The percentages of cells with puncta were calculated by
examining over 100 GFP positive cells. All values were expressed as means ± SD of three independent experiments, each of which was done in
triplicate.
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12 hours after reversine treatment both in OC2 and
OCSL cells (Figure 5B). Interestingly, the pattern of LC3
in OC2 and OCSL cells under normal condition was dif-
ferent. Even without reversine stimulation, OC2 cells
showed endogenous LC3-II expression. Unlike in OC2,
the effect of reversine on LC3-II in OCSL cells was
more significant. Co-treatment of the autophagy inhibi-
tor 3-MA decreased reversine-induced LC3-II in both
cells, especially in OCSL cells (Figure 5B). This result
indicated that reversine could trigger autophagy and
might contribute to the caspase-independent pro-
grammed cell death. This possibility was further con-
firmed by the effect of reversine in LC3-II aggregation:
In OCSL cells ectopically expressing GFP-LC3. GFP-
LC3 showed diffuse pattern but became puncta pattern
if treated with reversine (Figure 5C). This puncta pat-
tern was not observed in the control cells harboring
GFP plasmid only in the presence of reversine or 3-MA,
ruling out the possibility of non-specific effects of the
drugs on puncta formation. Moreover, this puncta pat-
tern was totally abolished if co-treatment reversine with
autophagy inhibitor 3-MA (Figure 5C). The quantitative
r e s u l t sa r es h o w ni nF i g u r e5 D .T h e s ed a t ac o n f i r m e d
that reversine triggered autophagic flux in OSCC cells.
Reversine inhibits Akt/mTOR signaling pathway
Previous studies demonstrated that deregulation of
PI3K-Akt signaling was frequently observed in various
cancer cells including OSCC. For example, over-activa-
tion of Akt may enhance malignancy and resistance of
cancer cells through anti- apoptotic stress [42]. There-
fore, PI3K-Akt pathway became a promising target for
cancer therapy recently [43]. In addition, aurora kinases
were also proven as an upstream regulator of Akt activ-
ity in several cancers recently [44]. Since reversine was
an inhibitor of aurora kinase, the effect of reversine on
Akt activity deserved further investigations. As expected,
reversine notably reduced the phosphorylation of Akt as
well as downstream factors, including mTOR complex 1
(mTORC1) and p70S6K within 12 hours (Figure 6). On
the contrary, although phospho-Jnk was affected slightly
at later time, reversine showed no significant influence
on the activation of MAPKs pathway (Additional file 2).
These results indicated that reversine selectively down-
regulated Akt/mTORC1 signaling pathway, resulting in
the suppression of cancer cell growth and induction of
autophagy.
Discussion
Our previous studies have characterized two OSCC cell
lines, OC2 and OCSL, which were established from buc-
cal specimens of two Taiwanese male patients with habit
of betel-quid chewing. The OCSL cells showed greater
proliferation, horizontal and vertical migration, and
transwell invasion abilities in comparison with OC2
cells [32]. In this study, we demonstrated that reversine
suppressed the growth of these two OSCC cells. One of
the mechanisms for such suppression is that reversine
retards cell cycle at G2/M stage, which was evidenced
by the prolonged expression of cyclin B1. This was also
observed in the treatment of another aurora kinase inhi-
bitor VX680 in HeLa cells [25,45]. However, we found
that cyclin B1 decreased later in the treatment concur-
rently with an increased level of cyclin D (Figure 2C).
This allows the cells to re-enter G1 phase, subsequently
leading to 4N or even 8N chromosome content in
OCSL cells (Figure 2B). Increase of polyploidy cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
Figure 6 Downregulation of Akt/mTORC1 signaling pathway by
reversine. OC2 cells (A) and OCSL cells (B) were treated with DMSO
or 10 μM reversine and harvested at indicated time points for
analyzing the indicated proteins, such as AKT, mTOR, p70S6K and
Beclin.
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ful cytokinesis. Consistent with this are growth arrest
and polyploidy observed in HeLa, CWR22Rv1, DU-145
and HCT-116 cells after reversine treatment [25,30,46].
We also demonstrated that reversine can trigger apop-
tosis, especially in the malignant OCSL cells (Figure
3A). The detail mechanism by which reversine triggers
apoptosis remains unclear. However, we noticed that the
amount of phosphorylated aurora kinases was slightly
higher in OC2 than that in OCSL (Additional File 1,
Figure S1). Previous study showed that aurora kinase A
overexpression can override the mitotic spindle assem-
bly checkpoint and induce resistance to taxol [47]. This
study may explain why OC2 is more resistant to rever-
sine. Moreover, VX680 selectively kills cells that overex-
press c-myc. In other words, VX680 is more efficient to
induce apoptosis in cells in a c-myc dependent but p53
independent manner [23]. In OSCC, p53 mutation and
c-myc amplification were observed [48]. In OC2 and
OCSL cells, both have mutated p53 but have the similar
level of c-myc [49 and our unpublished date]. However,
we did not rule out the possibility that these two OSCC
cells potentially have mutated c-myc with different
activity. Furthermore, inhibitor of aurora kinase B,
ZM447439, suppresses the growth of cervical cancer
SiHa cells and enhances the chemosensitivity to Cispla-
tin [50]. These studies provided the hint why OCSL was
more sensitive to reversine.
Aurora kinases had been reported to participate in
several signaling pathways like PI3K-Akt [44]. Here we
show that reversine may inhibit the activity of Akt,
which is frequently over-activated in many cancers
[42,43]. Besides, mTORC1, the downstream factor of
Akt, is also critical for cell proliferation and correlated
to carcinogenesis [51]. Actually, mTORC1 phosphory-
lates 4E-BP1 to release eIF4E and affects the phosphory-
lation of ribosomal protein S6 through p70S6K [52].
Therefore, mTORC1 functions as a regulator for protein
synthesis [53]. Interestingly, although reversine affects
the activities of mTORC1 pathway, its final influence on
translation machinery is not global based on the con-
stant expression of Beclin 1 (Figure 6A). How the speci-
ficity was regulated still remains unclear.
In addition to proteins translation pathway, the role of
mTORC1 is correlated to autophagy control [54]. Like
double-edged sword, autophagy could have opposite
effects on tumor cells [55]. Modest autophagy may help
neoplasia cells survive under harsh environments
[56,57]. Autophagy could play the protective role that
impedes the cell death by reducing the occurrence of
intrinsic apoptosis through mitochondria consumption
[58,59]. On the contrary, autophagy was also reported to
be disadvantageous for cancer cells [55-57]. Therefore,
several autophagy-based chemicals are being tested for
cancer therapy [60]. Our results showed that reversine
enhances autophagy significantly in malignant OCSL
cells, but weakly in less-malignant OC2 (Figure 5B). Fig-
ure 3A also suggested that reversine triggered apoptosis
more effectively in OCSL cells. These discrepancies may
be also suitable for differentiation between normal cells
and cancer cells, which will be a tremendous advantage
for the clinical application. Even under normal culture
condition, we noticed that OC2 cells have high level of
endogenous autophagy based on the constitutive expres-
sion of LC3-II (Figure 5B). Since OC2 cells is a less
malignant cell line with the characteristics of squamous
cells, it is highly possible that original OC2 cells may
take advantage of high basal autophagy to survive before
sufficient nutrients supply by angiogenesis in early carci-
nogenesis stage in vivo. Interestingly, inhibition of
mTORC1 by rapamycin induces no significant increase
of LC3-II in OCSL cells (data not shown), suggesting
other unknown pathways involved in this reversine-
induced autophagy in OCSL cells. The exact mechanism
for reversine-induced autophagy in OCSL cells deserved
to be verified.
Because several cancer cells were reported to have
mutations such as p53 and caspases to enhance resis-
tance against apoptotic stress, a multi-targeting strategy
against tumor cells may increase the chance to treat
cancers [61-65]. Here, we demonstrated that reversine is
a broad-spectrum antitumor agent that induces cell
cycle arrest, apoptosis, caspase-independent death and
autophagy, suggesting that either reversine itself or
reversine in combination with other drugs is a novel
therapeutic regimen for OSCC patients.
Conclusions
Oral cancer is one of the leading cancers in Taiwan due
to betel quid chewing. However, current chemotherapy
using Cisplatin and 5-Fu against OSCC remains ineffi-
cient to improve survival rate. Reversine suppresses
OSCC cells via multiple mechanisms, which may pro-
vide a new way advantageous for treating oral cancer.
Based on this study, evaluations of cellular sensitivity/
resistance to reversine itself or reversine in combination
with the current drugs Cisplatin and 5-Fu in cell culture
and in animal xenografts model deserve to be further
tested in the future.
Additional material
Additional file 1: Inhibition of aurora kinases activities by reversine.
(A) Aurora kinases were detectable in two OSCC cell lines, OC2 and
OCSL. (B) Reversine inhibited Serine 10 phosphorylation of histone H3 in
OSCC cells. Nocodazole treatment was used as a positive control.
Additional file 2: No significant influence on the activation of
MAPKs pathway by reversine. MAPK signaling pathway was not
changed significantly in reversine-induced cell death. Proteins involved in
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OCSL cells, respectively. The GAPDH protein was used as the loading
control.
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